AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart ...
Investor's Business Daily on MSN
Why AstraZeneca crashed 8%, leading three rivals, including Pfizer, to jump
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.
A U.S. appeals court on Thursday upheld a ruling for AstraZeneca against allegations that its ​blockbuster lung-cancer drug Tagrisso infringed patents owned by ‌Pfizer subsidiary Wyeth.
Pfizer (PFE) stock, Alnylam (ALNY) stock and BridgeBio (BBIO) stock jump after a trial setback for an ATTE-CM drug from Astra ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the ...
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results